Imigran

Sumatriptan, the active ingredient in Imigran, is a triptan presented as a 20 mg nasal spray for nasal use. It provides acute treatment of migraine attacks, with or without aura, in adult patients. It acts as a selective agonist of 5‑HT1B/1D receptors, producing cranial vasoconstriction and inhibition of trigeminal pain pathways.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides regulatory‑approved products to healthcare providers across multiple regions.

Imigran (sumatriptan) is indicated for the acute treatment of migraine, a neurovascular headache disorder.

- Migraine with aura: relief of headache and associated neurological symptoms. - Migraine without aura: rapid reduction of pain intensity. - Acute migraine attacks in adults: enables early intervention to stop progression of the attack.

Common Side Effects: - Nasal irritation or burning sensation. - Unpleasant taste or metallic taste. - Dizziness or light‑headedness. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Chest pain or tightness indicating possible coronary vasospasm. - Severe hypertension or hypertensive crisis. - Serotonin syndrome, especially when combined with serotonergic agents. - Allergic reactions such as rash, swelling, or anaphylaxis.

Before using Imigran, consider the following precautions: - Assess cardiovascular history: avoid in patients with ischemic heart disease or uncontrolled hypertension. - Avoid concomitant ergotamine or other vasoconstrictors: increased risk of severe vasospasm. - Do not use with MAO inhibitors within 24 hours: risk of serotonin syndrome. - Caution in patients with severe liver impairment: may affect drug clearance. - Store at room temperature: keep in the original container, protect from moisture and light.

Imigran may interact with several medication classes.

Major Interactions (Avoid): - Ergot alkaloids: additive vasoconstriction can precipitate coronary events. - Monoamine oxidase inhibitors (MAOIs): heightened risk of serotonin syndrome. - Other triptans: combined use may cause excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: monitor for signs of serotonin syndrome. - Beta‑blockers: may enhance hypotensive effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase sumatriptan plasma concentrations.